SANTA CLARA, Calif., Aug. 30, 2016 /PRNewswire/ -- Crown Bioscience, a wholly owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology and metabolic disease research, is pleased to announce that our President, Dr. Jean Pierre Wery, has now moved into the role of Chief Executive Officer.
In addition to Dr. Wery's recent nomination as CEO, Dr. Alex Wu, co-founder of CrownBio takes the role of President and Chief Strategy Officer, while Ms. Eva Ho has been appointed Chief Financial Officer.
"In 2016 CrownBio has experienced unprecedented growth with increasing demand for our Immuno-Oncology and Cardiovascular and Metabolic Disease services and models," says Wery. "As newly appointed CEO my objective is to foster the development of new products, cutting-edge technologies, and services for oncology and metabolic disease, while contemplating a possible expansion into new therapeutic areas."
To further demonstrate CrownBio's commitment to support its global growth, the Board of Directors has chosen Ms. Ho for the role of CFO. Ho brings years of experience in financial planning and analysis, having led the financial operations of well renowned global companies. Ho will take on Mr. Bing Zhu's previous role, who has now been appointed Chief Operating Officer.
"I am pleased Ms. Ho has joined CrownBio and I am looking forward to leading the next phase of the company's strategic initiatives," said Wu, CrownBio's co-founder and newly appointed President and CSO.
The consolidation of CrownBio's leadership team demonstrates the company's dedication to provide an experienced management team to drive forward the advancement of drug discovery worldwide.
For more information on CrownBio's commitment to furthering the field of oncology and metabolic disease drug discovery, visit www.crownbio.com.
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, please visit www.crownbio.com.
SOURCE Crown Bioscience Inc.